|1.||Michel, Martin C: 2 articles (03/2013 - 11/2012)|
|2.||Ellsworth, Pamela: 1 article (03/2015)|
|3.||Fantasia, Jennifer: 1 article (03/2015)|
|4.||Igawa, Yasuhiko: 1 article (03/2013)|
|5.||von Keitz, Alexander: 1 article (11/2012)|
|6.||Ohlstein, Eliot H: 1 article (11/2012)|
|7.||Wollmann, Jutta: 1 article (01/2010)|
|8.||Langer, Rupert: 1 article (01/2010)|
|9.||Schemann, Michael: 1 article (01/2010)|
|10.||Kober, Olivia I: 1 article (01/2010)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
11/01/2012 - "To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinical proof-of-concept study in incontinent women with overactive bladder (OAB). "
11/01/2012 - "A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder."
03/01/2015 - "Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder."
03/01/2013 - "β(3)-Adrenoceptor agonists are an emerging drug class for the treatment of the overactive bladder syndrome, and clinical proof-of-concept data have been obtained for three representatives of this class, mirabegron, ritobegron, and solabegron. "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)